drugset / Trial / NCT00620633

Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation

NCT00620633 ↗

NaSingle-groupOpen-labelTreatment

Summary

This study will test the safety of giving you specialized white cells from your donor. They are called WT1 sensitized T cells. They have been grown in the lab and are immunized against a protein. The protein is called the Wilms' tumor protein, or WT1. Your leukemic cells make too much of this protein. We want to learn whether the WT1 sensitized T cells will attack the protein and kill the leukemia cells.

Timeline

Start
2008-02-08
Primary completion
2021-02-26
Completion
2021-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject WT1-sensitized T cells Cell therapy — Intravenous